Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 2
1971 4
1972 2
1973 1
1974 1
1975 2
1976 2
1977 2
1980 3
1981 1
1982 3
1983 3
1984 2
1985 1
1986 7
1987 3
1989 4
1990 2
1993 1
1994 2
1995 1
1998 1
2002 1
2004 2
2005 1
2007 1
2008 2
2009 2
2012 1
2013 3
2014 2
2015 1
2016 2
2017 2
2018 6
2019 5
2020 8
2021 16
2022 8
2023 4
2024 6
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: sala ma. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia.
Grant RA, Morales-Nebreda L, Markov NS, Swaminathan S, Querrey M, Guzman ER, Abbott DA, Donnelly HK, Donayre A, Goldberg IA, Klug ZM, Borkowski N, Lu Z, Kihshen H, Politanska Y, Sichizya L, Kang M, Shilatifard A, Qi C, Lomasney JW, Argento AC, Kruser JM, Malsin ES, Pickens CO, Smith SB, Walter JM, Pawlowski AE, Schneider D, Nannapaneni P, Abdala-Valencia H, Bharat A, Gottardi CJ, Budinger GRS, Misharin AV, Singer BD, Wunderink RG; NU SCRIPT Study Investigators. Grant RA, et al. Nature. 2021 Feb;590(7847):635-641. doi: 10.1038/s41586-020-03148-w. Epub 2021 Jan 11. Nature. 2021. PMID: 33429418 Free PMC article.
Profibrotic monocyte-derived alveolar macrophages are expanded in patients with persistent respiratory symptoms and radiographic abnormalities after COVID-19.
Bailey JI, Puritz CH, Senkow KJ, Markov NS, Diaz E, Jonasson E, Yu Z, Swaminathan S, Lu Z, Fenske S, Grant RA, Abdala-Valencia H, Mylvaganam RJ, Ludwig A, Miller J, Cumming RI, Tighe RM, Gowdy KM, Kalhan R, Jain M, Bharat A, Kurihara C, San Jose Estepar R, San Jose Estepar R, Washko GR, Shilatifard A, Sznajder JI, Ridge KM, Budinger GRS, Braun R, Misharin AV, Sala MA. Bailey JI, et al. Among authors: sala ma. Nat Immunol. 2024 Nov;25(11):2097-2109. doi: 10.1038/s41590-024-01975-x. Epub 2024 Oct 4. Nat Immunol. 2024. PMID: 39367123 Free PMC article.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: sala ma. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.
Carrillo-García J, Hindi N, Conceicao M, Sala MÁ, Ugalde A, López-Pousa A, Bagué S, Sevilla I, Vicioso L, Ramos R, Martínez-Trufero J, Gómez Mateo MC, Cruz J, Hernández-León CN, Redondo A, Mendiola M, García JM, Hernández JE, Álvarez R, Agra C, de Juan-Ferré A, Valverde C, Cano JM, Sande LM, Pérez-Fidalgo JA, Lavernia J, Marcilla D, Gutiérrez A, Moura DS, Martín-Broto J. Carrillo-García J, et al. Among authors: sala ma. Eur J Cancer. 2024 Sep;209:114270. doi: 10.1016/j.ejca.2024.114270. Epub 2024 Aug 8. Eur J Cancer. 2024. PMID: 39142211
Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia.
Markov NS, Ren Z, Senkow KJ, Grant RA, Gao CA, Malsin ES, Sichizya L, Kihshen H, Helmin KA, Jovisic M, Arnold JM, Pérez-Leonor XG, Abdala-Valencia H, Swaminathan S, Nwaezeapu J, Kang M, Rasmussen L, Ozer EA, Lorenzo-Redondo R, Hultquist JF, Simons LM, Rios-Guzman E, Misharin AV, Wunderink RG, Budinger GRS, Singer BD, Morales-Nebreda L; NU SCRIPT Study Investigators. Markov NS, et al. Nat Immunol. 2024 Sep;25(9):1607-1622. doi: 10.1038/s41590-024-01914-w. Epub 2024 Aug 13. Nat Immunol. 2024. PMID: 39138384 Free PMC article.
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: sala ma. Clin Cancer Res. 2024 Nov 15;30(22):5180-5191. doi: 10.1158/1078-0432.CCR-24-0932. Clin Cancer Res. 2024. PMID: 39250635 Clinical Trial.
124 results